{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostate+Cancer&page=10&q=hormone-sensitive",
    "query": {
      "q": "hormone-sensitive",
      "condition": "Prostate Cancer",
      "page": 10
    },
    "page_size": 10
  },
  "pagination": {
    "page": 10,
    "page_size": 10,
    "total_count": 159,
    "total_pages": 16,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostate+Cancer&page=11&q=hormone-sensitive&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostate+Cancer&page=9&q=hormone-sensitive&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T14:08:27.958Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05079698",
      "title": "A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "177Lu-PSMA-617",
          "type": "DRUG"
        },
        {
          "name": "Stereotactic Body Radiotherapy (SBRT)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 29,
      "start_date": "2021-10-01",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2026-06-25",
      "last_synced_at": "2026-10-15T14:08:27.958Z",
      "location_count": 7,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05079698"
    },
    {
      "nct_id": "NCT07674771",
      "title": "Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Prostate Cancer",
        "Castration Sensitive Prostate Cancer",
        "Metastatic Prostate Cancer",
        "Adaptive Radiotherapy"
      ],
      "interventions": [
        {
          "name": "Drug: 68-Ga PSMA11",
          "type": "DRUG"
        },
        {
          "name": "Adaptive stereotactic ablative radiotherapy (SABR)",
          "type": "RADIATION"
        },
        {
          "name": "68Ga-PSMA-11",
          "type": "DRUG"
        },
        {
          "name": "Adaptive stereotactive ablative radiotherapy (SABR)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 30,
      "start_date": "2026-10",
      "completion_date": "2029-06-15",
      "has_results": false,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-10-15T14:08:27.958Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07674771"
    },
    {
      "nct_id": "NCT06894511",
      "title": "An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Castration Resistant Prostate Cancer (mCRPC)"
      ],
      "interventions": [
        {
          "name": "AAA617",
          "type": "DRUG"
        },
        {
          "name": "ARPI: Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "ARPI: Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "MALE",
        "summary": "18 Years to 100 Years · Male only"
      },
      "enrollment_count": 7,
      "start_date": "2025-09-11",
      "completion_date": "2026-10-15",
      "has_results": false,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-10-15T14:08:27.958Z",
      "location_count": 5,
      "location_summary": "Casa Grande, Arizona • Gilbert, Arizona • Newport Beach, California + 2 more",
      "locations": [
        {
          "city": "Casa Grande",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06894511"
    },
    {
      "nct_id": "NCT07779590",
      "title": "A Study to Learn About the Outcomes Between Study Medicines, Enzalutamide and Darolutamide Among Men With Metastatic Castration Sensitive Prostate Cancer (mCSPC)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Metastatic Castration Sensitive Prostate Cancer (mCSPC)"
      ],
      "interventions": [
        {
          "name": "darolutamide plus androgen deprivation therapy",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide plus androgen deprivation therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 4700,
      "start_date": "2026-08-19",
      "completion_date": "2026-11-15",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-10-15T14:08:27.958Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07779590"
    },
    {
      "nct_id": "NCT04493853",
      "title": "Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hormone-Sensitive Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Capivasertib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Abiraterone Acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "MALE",
        "summary": "18 Years to 130 Years · Male only"
      },
      "enrollment_count": 1012,
      "start_date": "2020-07-13",
      "completion_date": "2027-03-31",
      "has_results": true,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-10-15T14:08:27.958Z",
      "location_count": 33,
      "location_summary": "Tucson, Arizona • La Jolla, California • Orange, California + 29 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04493853"
    },
    {
      "nct_id": "NCT04658849",
      "title": "Insulin Resistance Following ADT for Prostate CA",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Insulin Resistance",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Pioglitazone 30 Mg Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Pioglitazone placebo tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Louis University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "MALE",
        "summary": "18 Years to 85 Years · Male only"
      },
      "enrollment_count": 0,
      "start_date": "2020-12-02",
      "completion_date": "2023-03-29",
      "has_results": false,
      "last_update_posted_date": "2023-05-15",
      "last_synced_at": "2026-10-15T14:08:27.958Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04658849"
    },
    {
      "nct_id": "NCT00058214",
      "title": "Perifosine in Treating Patients With Recurrent Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma of the Prostate",
        "Recurrent Prostate Cancer",
        "Stage IIB Prostate Cancer",
        "Stage III Prostate Cancer",
        "Stage IV Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "perifosine",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 25,
      "start_date": "2003-03",
      "completion_date": "2009-01",
      "has_results": true,
      "last_update_posted_date": "2015-02-23",
      "last_synced_at": "2026-10-15T14:08:27.958Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00058214"
    },
    {
      "nct_id": "NCT05276492",
      "title": "Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer",
        "Prostate Adenocarcinoma",
        "Prostate Neoplasm",
        "Prostate Cancer Metastatic"
      ],
      "interventions": [
        {
          "name": "Abiraterone Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Prednisone tablet",
          "type": "DRUG"
        },
        {
          "name": "Drug Dairy/Log",
          "type": "OTHER"
        },
        {
          "name": "Low-fat meal",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2023-01-24",
      "completion_date": "2024-11-16",
      "has_results": false,
      "last_update_posted_date": "2025-10-03",
      "last_synced_at": "2026-10-15T14:08:27.958Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05276492"
    },
    {
      "nct_id": "NCT02349386",
      "title": "Maintaining Suppression of Testosterone With Transdermal Estradiol Gel",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer of the Prostate"
      ],
      "interventions": [
        {
          "name": "BHR-200 (0.36% transdermal 17β-estradiol gel)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BHR Pharma, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 34,
      "start_date": "2015-07",
      "completion_date": "2018-01-10",
      "has_results": true,
      "last_update_posted_date": "2022-03-31",
      "last_synced_at": "2026-10-15T14:08:27.958Z",
      "location_count": 12,
      "location_summary": "Tucson, Arizona • Aventura, Florida • Daytona Beach, Florida + 9 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Aventura",
          "state": "Florida"
        },
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Council Bluffs",
          "state": "Iowa"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02349386"
    },
    {
      "nct_id": "NCT03649841",
      "title": "Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Castration-Sensitive Prostate Carcinoma",
        "Metastatic Malignant Neoplasm in the Bone",
        "Metastatic Prostate Carcinoma",
        "Prostate Adenocarcinoma",
        "Prostate Small Cell Neuroendocrine Carcinoma",
        "Stage IV Prostate Cancer AJCC v8",
        "Stage IVA Prostate Cancer AJCC v8",
        "Stage IVB Prostate Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Antiandrogen Therapy",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone Acetate",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 10,
      "start_date": "2020-06-29",
      "completion_date": "2023-02-01",
      "has_results": true,
      "last_update_posted_date": "2023-10-26",
      "last_synced_at": "2026-10-15T14:08:27.958Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03649841"
    }
  ]
}